CA-AEVA,-INC.
8.9.2020 15:02:12 CEST | Business Wire | Press release
Aeva, a leader in next generation sensing and perception systems, and ZF, a top global automotive Tier-1 supplier, are partnering to bring the world’s first Frequency Modulated Continuous Wave (FMCW) LiDAR to the automotive market. The partnership — Aeva's expertise in FMCW LiDAR technology combined with ZF's experience in industrialization of automotive grade sensors — represents a key commitment to accelerate mass production of safe and scalable 4D LiDAR technology for autonomous driving applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200908005368/en/
“From early on we have believed in building an ecosystem of the world’s most capable partners across the industry and this partnership is one part of that plan. ZF’s capability as one of the largest Tier-1s globally with expertise in automotive scale production of sensing systems is a key step to accelerating the introduction of safe and scalable autonomous vehicles,” said Soroush Salehian, Co-Founder of Aeva. “The industry is at the cusp of deploying the next generation of sensing to realize the adoption of highly automated and autonomous cars and we believe Aeva’s 4D LiDAR will be an indispensable part of this next chapter.”
About the Partnership
Aeva and ZF aim to bring the first automotive grade 4D LiDAR to market for autonomous driving applications. The partnership strengthens the parties’ collaboration by leveraging Aeva’s unique expertise in FMCW LiDAR and perception technology together with ZF’s expertise as a leading automotive supplier, autonomous systems provider, and market leader in smart cameras and the corresponding production know-how. The final system is targeted as a key solution for autonomous driving applications including established truck and OEM manufacturers as well as leading mobility as a service customers.
“LiDAR is a key technology for systems and sensing in the area of highly automated and autonomous driving. Aeva’s unique FMCW technology combines long range performance and direct velocity measurements, making it the right choice for autonomous driving applications. We have seen that different markets require different solutions. For L2+/L3 systems a package and cost optimized Lidar is crucial. For applications which feature L4 and further solutions, the focus lies on range and direct velocity measurement, as edge performance is key for the virtual driver software stack.
Aeva’s FMCW technology approach perfectly meets all the stringent requirements for autonomous operations in trucks and robo-service vehicles. We look forward to bring the world’s first FMCW LiDAR to an automotive grade level and scale production, where ZF can rely on a long-lasting production experience in optical sensors. ‘Automotive Grade’ will become a quality seal, necessary for a solid business model of all autonomous vehicle software stack providers,” said Torsten Gollewski, Executive Vice President Autonomous Mobility Solutions at ZF.
As part of the partnership, Aeva will be responsible for the FMCW LiDAR core sensing functionality, performance and algorithms and ZF will be responsible for industrialization of the automotive grade sensing system that meets all automotive requirements.
What makes Aeva’s 4D LiDAR unique?
Aeva’s FMCW technology is designed to meet the challenging performance and the manufacturability requirements for adoption of LiDAR in autonomous vehicles.
Unlike other LiDAR technologies, Aeva’s 4D LiDAR-on-chip uses a continuous laser beam to measure the change in frequency of the waveform as it reflects off of an object. This allows it to detect an object’s range and instant velocity simultaneously beyond 300 meters at high accuracy. Aeva’s 4D LiDAR is also completely free of interference from other sensors or sunlight and it operates at only fractions of the optical power typically required to achieve long range performance. All of which are critical hurdles that have previously slowed the broad adoption of automotive LiDAR.
Aeva’s technology also differs from other FMCW approaches in its unique ability to break the dependency between maximum range and points density. Aeva’s 4D LiDAR integrates multiple beams on a chip that is produced at silicon wafer scale. Each beam is uniquely capable of measuring multiple millions of points per second at maximum range providing unprecedented data fidelity and significantly enhancing the factor of safety for self-driving cars.
About Aeva
Aeva was founded in 2017 by Soroush Salehian, and Mina Rezk -- previously engineering leaders at Apple & Nikon. Headquartered in Mountain View, California, Aeva is building the next-generation of sensing and perception for autonomous vehicles that is safe, simple, and scalable. Aeva is backed by Volkswagen’s Porsche SE, Lux Capital and Canaan Partners, amongst others. For more information, visit www.aeva.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200908005368/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
